Jillian Parsons, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 E Decatur St, West Point, NE 68788 Phone: 402-372-2404 Fax: 402-372-6770 |
Zachary J Wordekemper, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 430 N Monitor St, West Point, NE 68788 Phone: 402-372-6717 |
Mrs. Renae Marie Meyer, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 E Decatur St, West Point, NE 68788 Phone: 402-372-2477 Fax: 402-372-6770 |
Scott D Green, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 East Decatur, West Point, NE 68788 Phone: 402-372-2477 Fax: 402-372-6770 |
Dr. Rhett J Eckmann, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 East Decatur, West Point, NE 68788 Phone: 402-372-2477 Fax: 402-372-6770 |
Dr. Thomas W Cohee, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 East Decatur, West Point, NE 68788 Phone: 402-372-2477 Fax: 402-372-6770 |
Dr. Brian E Hass, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 East Decatur, West Point, NE 68788 Phone: 402-372-2477 Fax: 402-372-6770 |
Natalie Tymkowych, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 E Decatur St, West Point, NE 68788 Phone: 402-372-2477 Fax: 402-372-6770 |
News Archive
The beneficial effects of six months of testosterone treatment on muscle mass, strength and quality of life in frail elderly men are not maintained at six months post-treatment, according to a study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
AxoGen, Inc., the parent company of AxoGen Corporation, has announced completion of the merger between LecTec Corporation and AxoGen Corporation.
According to a new Cornell University study, when moviegoers were served stale popcorn in big buckets, they ate 34 percent more than those given the same stale popcorn in medium-sized containers.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for evolocumab seeking approval for the treatment of high cholesterol.
› Verified 3 days ago